BHT-3009 for Multiple Sclerosis
BHT-3009 is Bayhill’s lead investigational drug developed from the BHT-DNA platform. The company has recently completed a phase II trial of BHT-3009 in Relapsing Remitting Multiple Sclerosis. The results are posted in the clinical trials section of our web site. Bayhill is planning on initiating a multi-center, randomized, blinded, placebo-controlled Phase IIb trial evaluating BHT-3009 for the treatment of Relapsing-Remitting Multiple Sclerosis in the fourth quarter of 2008.


BHT-3021 for Type 1 Diabetes
Bayhill Therapeutics is currently conducting a multi-center, randomized, blinded, placebo-controlled cross over phase I/II trial evaluating BHT-3021 for the treatment of type 1 diabetes in type 1 diabetic patients. BHT-3021 is Bayhill’s second investigational drug developed from the BHT-DNA platform. The goal of BHT-3021 is to reduce or eliminate the immune system’s attack on the pancreas, thereby shutting down the disease process which gives rise to type 1 diabetes.


Additional data for both physicians and patients regarding both of these trials will be posted on this page in the near future.